biotechnology

Biotech Adam Feuerstein

STAT Plus: Roivant acquires drug for pulmonary hypertension from Bayer

Politics John Wilkerson

STAT Plus: House passes bill that targets China biotechs

The Readout Meghana Keshavan

STAT Plus: Terns’ GLP-1 pill leads to weight loss in early study

Biotech Adam Feuerstein

STAT Plus: Merck executive plays down impact of new lung cancer drug data on Keytruda

Biotech Angus Chen

STAT Plus: Relay discloses encouraging results for experimental breast cancer treatment

Biotech Matthew Herper

STAT Plus: With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights

Biotech Jonathan Wosen and Adam Feuerstein

STAT Plus: Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial

Biotech Adam Feuerstein

STAT Plus: Vor Biopharma’s ‘shielded’ transplant delays relapse in leukemia patients

The Readout LOUD Elaine Chen, Allison DeAngelis, and Adam Feuerstein

Summit’s upcoming cancer results, Recursion’s mixed data, and a new co-host

Pharma Jason Mast

STAT Plus: U.K. charities give $36 million to start new drugs for childhood tumors 

Pharma Matthew Perrone and Nicky Forster — Associated Press

STAT Plus: Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after Covid delays

The Readout Meghana Keshavan

STAT Plus: Lilly has more positive data on its weekly insulin

Adam's Take Adam Feuerstein

STAT Plus: Alnylam versus BridgeBio: The ATTR-CM debate

Biotech Adam Feuerstein

STAT Plus: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal

The Readout Elaine Chen

STAT Plus: BioMarin’s big day today

Exclusive Allison DeAngelis

STAT Plus: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance

The Readout Meghana Keshavan

STAT Plus: The biotech news you need to read this morning

Biotech Andrew Joseph

STAT Plus: European court sides with Illumina, saying regulators overstepped in scrutiny of Grail deal

Special Report Matthew Herper

Diagnosed with cancer, a pharmaceutical executive became a patient advocate and changed drug development. It took decades

Biotech Andrew Joseph

STAT Plus: Detailed data on Alnylam’s heart drug show substantial benefit, while competition likely awaits

Biotech Andrew Joseph

STAT Plus: Wegovy cut patients’ chances of dying from Covid-19, new analysis shows

Biotech Elaine Chen

STAT Plus: New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure

The Readout LOUD Allison DeAngelis, Elaine Chen, and Adam Feuerstein

Jim Wilson’s next venture, a surprise startup shutdown, & Lilly’s Zepbound strategy

Adam's Biotech Scorecard Adam Feuerstein

STAT Plus: Thoughts, takes, and burning biotech questions as the beginning of the end of the year approaches

The Readout Meghana Keshavan

STAT Plus: Genentech is shedding even more employees

Health tech Katie Palmer and Nicholas Florko

STAT Plus: The weight loss drug shortage is driving patients to Hims. What happens when the shortage ends?

The Readout Elaine Chen

STAT Plus: Hims takes a blow from Lilly’s vial news

Biotech Adam Feuerstein

STAT Plus: Neurocrine reports mixed results on schizophrenia therapy in mid-stage trial

The Readout Elaine Chen

STAT Plus: Pfizer and Lilly want to sell you drugs directly